Skip to main content
Equibles
IRWD logo

IRWD · Ironwood Pharmaceuticals Inc

Track IRWD — free

Use IRWD with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$4.42 +0.15 (+3.51%)
Russell 2000 member Rebalance outlook locked
Market Cap
$705.57M
Shares
165.24M

IRWD metrics

74 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.27
Market cap
$705.57M

Price action

19 metrics
Price change (1W)
-2.7%
Price change (30D)
-3.4%
Price change (3M)
+30.2%
Price change (6M)
+17.3%
Price change (YTD)
+26.7%
Price change (1Y)
+223.5%
Trailing year
Price change (5Y)
-67.8%
52-week high
$5.39
52-week low
$1.10
Change from 52-week high
-20.8%
Change from 52-week low
+288.2%
Annualized volatility
97.1%
Beta
1.9
RSI (14D)
52.3
Price vs SMA 50
+2.9%
Price vs SMA 200
+8.9%
Avg volume (3M)
2.22M
Relative volume
0.7
Average dollar volume
$9.02M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
165.24M

Valuation

12 metrics
P / E (TTM)
5.5
Trailing earnings · reciprocal yield 18.0%
PEG ratio
0.0
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.8×
reciprocal yield 55.2%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
17.9%
P / FCF
—
P / operating cash flow
3.8
reciprocal yield 26.3%
Earnings yield
18.4%

Historical valuation

8 metrics
P / E historical average (3Y)
31.8×
reciprocal yield 3.1%
P / E historical average (5Y)
17.9×
reciprocal yield 5.6%
EV / revenue historical average (3Y)
2.4×
reciprocal yield 41.5%
EV / revenue historical average (5Y)
2.9×
reciprocal yield 34.2%
EV / EBIT historical average (3Y)
4.8×
reciprocal yield 20.6%
EV / EBIT historical average (5Y)
5.7×
reciprocal yield 17.6%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
17.9%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
60.1%
Trailing 12 months
Net margin
33.4%
Gross profit (TTM)
—
Operating profit (TTM)
$234.17M
Net income (TTM)
$129.87M
Trailing 12 months
Diluted EPS (TTM)
$0.77
FCF margin
—
Effective tax rate
37.4%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+32.6%
Year over year
Net income growth YoY
+117.3%
Revenue (TTM)
$389.32M
Trailing 12 months
EPS growth YoY
+121.4%
Shares change YoY
-5.5%
Year over year · fewer shares
Revenue CAGR (3Y)
-10.3%
Revenue CAGR (5Y)
-5.3%
EPS CAGR (3Y)
-46.1%
EPS CAGR (5Y)
-25.6%
FCF CAGR (3Y)
-22.6%
FCF CAGR (5Y)
-5.3%

Quality

14 metrics
Return on equity
—
Return on assets
45.5%
Debt / equity
—
Current ratio
6.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
7.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$79.13M
Total assets
$285.13M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$185.56M
Capital expenditures (TTM)
$35,000
R&D (TTM)
$88.69M
SG&A (TTM)
$64.55M
Stock compensation (TTM)
$14.32M
R&D / revenue
22.8%
Stock compensation / revenue
3.7%

Ownership (13F)

3 metrics
13F filers
212
13F filer change QoQ
-15
Institutional ownership
97.6%

Short interest

3 metrics
Short interest
10.9%
Latest settlement · 6.4 days to cover
Days to cover
6.4d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$658,523
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1446847 CUSIP 46333X108 13F (30d) 177 filings 174 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)